구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 12-Day Production of Car-T Cells (12-Day Production of Car-T Cells) Medical College of Wisconsin·Non Hodgkin Lymphoma (NHL) 2 trials |
|---|---|
Overview Program | 12-Day Production of Car-T Cells |
Overview Company | Medical College of Wisconsin |
Overview Modality | CGT |
Overview Target | Non Hodgkin Lymphoma (NHL) |
Overview Indication | Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory |
MoA Mechanism | targeted CD19 chimeric antigen receptor |
MoA Biomarker | CD20 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Grade 1 to 2 immune effector cell-associated neurotoxicity syndrome occurred in 2 patients and resolved spontaneously. |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.. The point-of-care, automated manufacturing of chimeric antigen receptor (CAR) T cells can reduce the waiting window and increase the therapy accessibility to patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) as compared with commercially availabl… |
Toxicology CRS | Reported |
Clinical Safety signal | Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.. The point-of-care, automated manufacturing of chimeric antigen receptor (CAR) T cells can reduce the waiting window and increase the therapy accessibility to patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) as compared with commercially availabl… |
Clinical Program phase | PHASE_2 |
Preclinical Animal (cat.) | Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | 12-Day Production of Car-T Cells (12-Day Production of Car-T Cells) Medical College of Wisconsin·Non Hodgkin Lymphoma (NHL) 2 trials |
|---|---|
Overview Program | 12-Day Production of Car-T Cells |
Overview Company | Medical College of Wisconsin |
Overview Modality | CGT |
Overview Target | Non Hodgkin Lymphoma (NHL) |
Overview Indication | Non Hodgkin Lymphoma (NHL); Mantle Cell Lymphoma (MCL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory |
MoA Mechanism | targeted CD19 chimeric antigen receptor |
MoA Biomarker | CD20 expression |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Grade 1 to 2 immune effector cell-associated neurotoxicity syndrome occurred in 2 patients and resolved spontaneously. |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.. The point-of-care, automated manufacturing of chimeric antigen receptor (CAR) T cells can reduce the waiting window and increase the therapy accessibility to patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) as compared with commercially availabl… |
Toxicology CRS | Reported |
Clinical Safety signal | Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.. The point-of-care, automated manufacturing of chimeric antigen receptor (CAR) T cells can reduce the waiting window and increase the therapy accessibility to patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) as compared with commercially availabl… |
Clinical Program phase | PHASE_2 |
Preclinical Animal (cat.) | Mouse, In vitro |
추천 비교
추천 비교